Features and treatment outcome of 9 patients with acute promyelocytic leukemia receiving intrathecal chemotherapy for treatment or prophylaxis of central nervous system leukemia
| Case* . | Sex/age, y . | Status at treatment . | Intrathecal chemotherapy . | Additional treatment . | Systemic relapse (time)† . | Outcome (follow-up) . | ||
|---|---|---|---|---|---|---|---|---|
| Systemic . | CNS . | Purpose . | Medication (times) . | |||||
| 1 | F/67 | CR3 | Relapse‡ | Treatment | MTX + Ara-C (6) | None | Yes (12 mo) | CR4, refused AHSCT, (14+ mo) |
| 2 | M/38 | CR3 | Relapse‡ | Treatment | MTX + Ara-C (6) | None | Yes (13 mo) | CR5 after AHSCT (14+ mo) |
| 3 | M/65 | CR3 | Normal | Prophylaxis | MTX (3) | None | Yes (10 mo) | Refused AHSCT, died of relapse (14 mo) |
| 4 | M/65 | CR3 | Normal | Prophylaxis | MTX (3) | None | No | CR3 (3+ mo) |
| 5 | M/29 | CR2 | Normal | Prophylaxis | MTX (3) | None | No | CR2 (2+ mo), on As2O3 |
| 6 | M/44 | CR2 | Relapse‡ | Treatment | MTX + Ara-C (19)§ | Cranial irradiation | No | CR2 (24+ mo) |
| 7 | M/69 | CR3 | Relapse‡ | Treatment | MTX + Ara-C (9) | Cranial irradiation | Yes (28 mo) | Died of relapse (28 mo) |
| 8 | M/46 | CR3 | Relapse‡ | Treatment | MTX + Ara-C (17)‖ | None | Yes (7 mo) | Died of relapse (12 mo) |
| 9 | M/47 | CR3 | Normal | Prophylaxis | MTX (3) | None | No | CR3 (3+ mo) |
| Case* . | Sex/age, y . | Status at treatment . | Intrathecal chemotherapy . | Additional treatment . | Systemic relapse (time)† . | Outcome (follow-up) . | ||
|---|---|---|---|---|---|---|---|---|
| Systemic . | CNS . | Purpose . | Medication (times) . | |||||
| 1 | F/67 | CR3 | Relapse‡ | Treatment | MTX + Ara-C (6) | None | Yes (12 mo) | CR4, refused AHSCT, (14+ mo) |
| 2 | M/38 | CR3 | Relapse‡ | Treatment | MTX + Ara-C (6) | None | Yes (13 mo) | CR5 after AHSCT (14+ mo) |
| 3 | M/65 | CR3 | Normal | Prophylaxis | MTX (3) | None | Yes (10 mo) | Refused AHSCT, died of relapse (14 mo) |
| 4 | M/65 | CR3 | Normal | Prophylaxis | MTX (3) | None | No | CR3 (3+ mo) |
| 5 | M/29 | CR2 | Normal | Prophylaxis | MTX (3) | None | No | CR2 (2+ mo), on As2O3 |
| 6 | M/44 | CR2 | Relapse‡ | Treatment | MTX + Ara-C (19)§ | Cranial irradiation | No | CR2 (24+ mo) |
| 7 | M/69 | CR3 | Relapse‡ | Treatment | MTX + Ara-C (9) | Cranial irradiation | Yes (28 mo) | Died of relapse (28 mo) |
| 8 | M/46 | CR3 | Relapse‡ | Treatment | MTX + Ara-C (17)‖ | None | Yes (7 mo) | Died of relapse (12 mo) |
| 9 | M/47 | CR3 | Normal | Prophylaxis | MTX (3) | None | No | CR3 (3+ mo) |
CNS indicates central nervous system; MTX, methotrexate (12 mg); Ara-C, cytosine arabinoside (50 mg); CR, complete remission; and AHSCT, autologous hematopoietic stem cell transplantation.
Cases were arranged according to the alphabetical order of their names, not the order of presentation.
Time from first dose of intrathecal chemotherapy.
Relapse was meningeal without demonstrable leukemic mass lesions in the CNS.
Two courses of intrathecal chemotherapy, 12 doses for first course, 7 doses for second course.
Two courses of intrathecal chemotherapy, 12 doses for first course, 5 doses for second course.